Compounds > cassiarin a
Page last updated: 2024-11-12

cassiarin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cassiarin A: isolated from the leaves of Cassia siamea; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cassiarin A : An isoquinoline alkaloid that is pyrano[2,3,4-ij]isoquinoline substituted by a hydroxy group at position 8 and methyl groups at positions 2 and 5. It is isolated from the leaves of Cassia siamea and exhibits antiplasmodial activity against Plasmodium falciparum. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
CassiagenusA plant genus of the family FABACEAE. Many species of this genus, including the medicinal C. senna and C. angustifolia, have been reclassified into the Senna genus (SENNA PLANT) and some to CHAMAECRISTA.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID17756117
CHEMBL ID596396
CHEBI ID65596
MeSH IDM0515243

Synonyms (6)

Synonym
chebi:65596 ,
CHEMBL596396
cassiarin a
2,5-dimethylpyrano[2,3,4-ij]isoquinolin-8-ol
Q27134059
3,7-dimethyl-2-oxa-6-azatricyclo[7.3.1.05,13]trideca-1(12),3,5(13),7,9-pentaen-11-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID453922Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Synthesis and structure-activity relationships of cassiarin A as potential antimalarials with vasorelaxant activity.
AID1153348Cytotoxicity against human BT474 cells assessed as cell viability at 100 uM after 3 days by MTT assay relative to control2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives.
AID453923Selectivity index, ratio of IC50 for human MCF7 to IC50 for chloroquine-resistant Plasmodium falciparum 3D72009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Synthesis and structure-activity relationships of cassiarin A as potential antimalarials with vasorelaxant activity.
AID468048Antimalarial activity against Plasmodium falciparum 3D7 by Giemsa staining2009Journal of natural products, Oct, Volume: 72, Issue:10
Cassiarins C-E, antiplasmodial alkaloids from the flowers of Cassia siamea.
AID1153350Cytotoxicity against human SW620 cells assessed as cell viability at 100 uM after 3 days by MTT assay relative to control2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives.
AID1153355Binding affinity to calf thymus DNA assessed as melting temperature at 30 uM by thermal denaturation assay2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives.
AID453921Antimalarial activity against chloroquine-resistant Plasmodium falciparum 3D7 by giemsa stain2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Synthesis and structure-activity relationships of cassiarin A as potential antimalarials with vasorelaxant activity.
AID1153352Cytotoxicity against human KATO III cells assessed as cell viability at 100 uM after 3 days by MTT assay relative to control2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives.
AID453925Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic rings assessed as inhibition of phenylephrine-induced tissue contraction2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Synthesis and structure-activity relationships of cassiarin A as potential antimalarials with vasorelaxant activity.
AID453924Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic rings assessed as inhibition of phenylephrine-induced tissue contraction at 30 uM2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Synthesis and structure-activity relationships of cassiarin A as potential antimalarials with vasorelaxant activity.
AID1153353Cytotoxicity against human CaSki cells assessed as cell viability at 100 uM after 3 days by MTT assay relative to control2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives.
AID1153351Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM after 3 days by MTT assay relative to control2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives.
AID453926Vasorelaxant activity in Wistar rat endothelium-removed thoracic aortic rings assessed as inhibition of phenylephrine-induced tissue contraction2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
Synthesis and structure-activity relationships of cassiarin A as potential antimalarials with vasorelaxant activity.
AID1153349Cytotoxicity against human ChaGo cells assessed as cell viability at 100 uM after 3 days by MTT assay relative to control2014Bioorganic & medicinal chemistry letters, Jul-01, Volume: 24, Issue:13
Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (75.00)29.6817
2010's2 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.06 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.0510aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
phenylephrine
Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.		2.0510phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
acetylene
[no description available]		2.0410alkyne;
gas molecular entity;
terminal acetylenic compound
ng-nitroarginine methyl ester
NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.		2.0510alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
amonafide
xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor		2.110isoquinolines
omega-n-methylarginine
omega-N-Methylarginine: A competitive inhibitor of nitric oxide synthetase.. N(omega)-methyl-L-arginine : A L-arginine derivative with a N(omega)-methyl substituent.		2.0510amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		02.0510
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.0510
Infections, Plasmodium
[description not available]		02.0410
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.0410